hydroxychloroquine has been researched along with Hypermelanosis in 36 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day." | 7.74 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
| " The aim of this report was to draw attention to the localized mucocutaneous bluish-grey hyperpigmentation induced by hydroxychloroquine with a case presentation and a review of the literature." | 7.74 | Hydroxychloroquine-induced hyperpigmentation: a case report. ( Budak, BS; Gurbuz, U; Kacar, C; Melikoglu, M; Melikoglu, MA, 2008) |
| "Hydroxychloroquine is an antimalarial agent, most commonly prescribed in the treatment of several rheumatic diseases." | 5.51 | Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine. ( Cai, L; Liu, X; Zhang, J; Zhang, S; Zhou, C, 2019) |
| "The hydroxychloroquine was indicated for systemic lupus erythematosus in 73." | 5.46 | Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. ( Bahloul, E; Bahloul, Z; Garbaa, S; Jallouli, M; Marzouk, S; Masmoudi, A; Turki, H, 2017) |
| "Two patients under imatinib and hydroxychloroquine treatment exhibited diffuse palatal hyperpigmentation and 2 patients treated with minocycline and golimumab showed multifocal pigmented macules." | 4.98 | Drug-associated hyperpigmentation of the oral mucosa: report of four cases. ( Kalogirou, EM; Sklavounou, A; Tosios, KI, 2018) |
| " The prolonged use of chloroquine and hydroxychloroquine can cause hyperpigmentation in the skin, oral mucosa and retinal pigment epithelium, which in turn can trigger toxicity in this epithelium, which in some cases causes vision loss." | 3.96 | Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus. ( Chacón-Dulcey, V; Frías, J; González, N; López-Labady, J; Pérez Alfonzo, R; Tirado, W; Villarroel-Dorrego, M, 2020) |
| "A 57-year-old woman with systemic lupus erythematosus and Sjögren syndrome presented with blue-grey hyperpigmentation of the face, upper back, and dorsal aspects of the feet after seven years of therapy with hydroxychloroquine." | 3.79 | Hydroxycholoroquine-induced hyperpigmentation. ( Boyd, KP; McLellan, B; Meehan, SA; Mir, A, 2013) |
| "We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day." | 3.74 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008) |
| " The aim of this report was to draw attention to the localized mucocutaneous bluish-grey hyperpigmentation induced by hydroxychloroquine with a case presentation and a review of the literature." | 3.74 | Hydroxychloroquine-induced hyperpigmentation: a case report. ( Budak, BS; Gurbuz, U; Kacar, C; Melikoglu, M; Melikoglu, MA, 2008) |
| "9 years, and the mean drug dosage was 244 mg." | 2.82 | Oral pigmentation as an adverse effect of chloroquine and hydroxychloroquine use: A scoping review. ( Blumenberg, C; Cardoso, SV; Franco, A; Oliveira, MB; Paranhos, LR; Silva, PUJ; Siqueira, WL; Vieira, W, 2022) |
| "Hydroxychloroquine is an immunomodulatory drug that has been used for 60 years to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis, and potential new uses and benefits continue to emerge." | 2.58 | Hydroxychloroquine: An old drug with new relevance. ( Collamer, AN; Shippey, EA; Wagler, VD, 2018) |
| "Hydroxychloroquine is an antimalarial agent, most commonly prescribed in the treatment of several rheumatic diseases." | 1.51 | Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine. ( Cai, L; Liu, X; Zhang, J; Zhang, S; Zhou, C, 2019) |
| "The hydroxychloroquine was indicated for systemic lupus erythematosus in 73." | 1.46 | Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. ( Bahloul, E; Bahloul, Z; Garbaa, S; Jallouli, M; Marzouk, S; Masmoudi, A; Turki, H, 2017) |
| "Hydroxychloroquine (HCQ) was initially indicated for the treatment of malaria, but more recently its anti-inflammatory and immune modulating properties have been utilized for treatment of multiple dermatologic and rheumatologic diseases." | 1.35 | Persistent cutaneous hyperpigmentation due to hydroxychloroquinone one year after therapy discontinuation. ( Heffernan, MP; Morrison, LK; Nordlund, JJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 6 (16.67) | 29.6817 |
| 2010's | 20 (55.56) | 24.3611 |
| 2020's | 9 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silva, PUJ | 1 |
| Oliveira, MB | 1 |
| Vieira, W | 1 |
| Cardoso, SV | 1 |
| Blumenberg, C | 1 |
| Franco, A | 1 |
| Siqueira, WL | 1 |
| Paranhos, LR | 1 |
| Alhassan, E | 1 |
| Al-Hassan, L | 1 |
| Chacón-Dulcey, V | 1 |
| López-Labady, J | 1 |
| Villarroel-Dorrego, M | 1 |
| Frías, J | 1 |
| Tirado, W | 1 |
| González, N | 1 |
| Pérez Alfonzo, R | 1 |
| Cristián Fischer, L | 1 |
| Matías Sanhueza, M | 1 |
| Bajoghli, A | 1 |
| Hernandez, G | 1 |
| Cardis, MA | 1 |
| Bhanja, DB | 1 |
| Sil, A | 1 |
| Chandra, A | 1 |
| Biswas, SK | 1 |
| Subramanyam, C | 1 |
| Wu, H | 1 |
| Puri, P | 1 |
| Chambers, CJ | 1 |
| Sivamani, RK | 1 |
| Muller, R | 1 |
| Jarrot, PA | 1 |
| Kaplanski, G | 1 |
| Bahloul, E | 1 |
| Jallouli, M | 3 |
| Garbaa, S | 1 |
| Marzouk, S | 1 |
| Masmoudi, A | 1 |
| Turki, H | 1 |
| Bahloul, Z | 1 |
| Tosios, KI | 1 |
| Kalogirou, EM | 1 |
| Sklavounou, A | 1 |
| Shippey, EA | 1 |
| Wagler, VD | 1 |
| Collamer, AN | 1 |
| Yeshurun, A | 1 |
| Bergman, R | 1 |
| Bathish, N | 1 |
| Khamaysi, Z | 1 |
| Zhang, S | 1 |
| Liu, X | 1 |
| Cai, L | 1 |
| Zhang, J | 1 |
| Zhou, C | 1 |
| Ivo, R | 1 |
| Lopes, CA | 1 |
| Reis, R | 1 |
| Horino, T | 1 |
| Ichii, O | 1 |
| Terada, Y | 1 |
| Stelton, CR | 1 |
| Connors, DB | 1 |
| Walia, SS | 1 |
| Walia, HS | 1 |
| Francès, C | 2 |
| Piette, JC | 2 |
| Huong, du LT | 1 |
| Moguelet, P | 1 |
| Factor, C | 1 |
| Zahr, N | 1 |
| Miyara, M | 1 |
| Saadoun, D | 1 |
| Mathian, A | 1 |
| Haroche, J | 1 |
| De Gennes, C | 1 |
| Leroux, G | 2 |
| Chapelon, C | 1 |
| Wechsler, B | 1 |
| Cacoub, P | 1 |
| Amoura, Z | 2 |
| Costedoat-Chalumeau, N | 2 |
| Tracy, CL | 1 |
| Blakey, B | 1 |
| Parker, G | 1 |
| Roebuck, J | 1 |
| Khayat, R | 1 |
| Dupuy, A | 1 |
| Pansé, I | 1 |
| Bagot, M | 1 |
| Cordoliani, F | 1 |
| Mir, A | 1 |
| Boyd, KP | 1 |
| Meehan, SA | 1 |
| McLellan, B | 1 |
| Kasper, RS | 1 |
| Flueckiger, B | 1 |
| Gobbi, S | 1 |
| Lautenschlager, S | 1 |
| Borelli, S | 1 |
| Sawalha, AH | 1 |
| Lau, JF | 1 |
| Dean, SM | 1 |
| Rooke, TW | 1 |
| Olin, JW | 1 |
| Puri, PK | 1 |
| Lountzis, NI | 1 |
| Tyler, W | 1 |
| Ferringer, T | 1 |
| Melikoglu, MA | 1 |
| Melikoglu, M | 1 |
| Gurbuz, U | 1 |
| Budak, BS | 1 |
| Kacar, C | 1 |
| Morrison, LK | 1 |
| Nordlund, JJ | 1 |
| Heffernan, MP | 1 |
| Ahiarah, A | 1 |
| Sauret, J | 1 |
| Halabi-Tawil, M | 1 |
| Morel, N | 1 |
| Kalabalikis, D | 1 |
| Patsatsi, A | 1 |
| Trakatelli, MG | 1 |
| Pitsari, P | 1 |
| Efstratiou, I | 1 |
| Sotiriadis, D | 1 |
| Vashi, N | 1 |
| Newlove, T | 1 |
| Chu, J | 1 |
| Patel, R | 1 |
| Stein, J | 1 |
| Cho, EB | 1 |
| Kim, BC | 1 |
| Park, EJ | 1 |
| Kwon, IH | 1 |
| Cho, HJ | 1 |
| Kim, KH | 1 |
| Kim, KJ | 1 |
| Kalampalikis, A | 1 |
| Goetze, S | 1 |
| Elsner, P | 1 |
| True, DG | 1 |
| Bryant, LR | 1 |
| Harris, MD | 1 |
| Bernert, RA | 1 |
| Millard, TP | 1 |
| Kirk, A | 1 |
| Ratnavel, R | 1 |
| Amichai, B | 1 |
| Gat, A | 1 |
| Grunwald, MH | 1 |
| Doutre, MS | 1 |
| Beylot, C | 1 |
| Beylot-Barry, M | 1 |
| Dumas, F | 1 |
4 reviews available for hydroxychloroquine and Hypermelanosis
| Article | Year |
|---|---|
Oral pigmentation as an adverse effect of chloroquine and hydroxychloroquine use: A scoping review.
Topics: Chloroquine; Cross-Sectional Studies; Humans; Hydroxychloroquine; Hyperpigmentation; Pigmentation | 2022 |
Drug-associated hyperpigmentation of the oral mucosa: report of four cases.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antirheumatic Agents; Biopsy; Female; Humans; H | 2018 |
Hydroxychloroquine: An old drug with new relevance.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythemato | 2018 |
Hydrochloroquine retinopathy: characteristic presentation with review of screening.
Topics: Aged; Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Female; Humans; Hydroxychloroqu | 2013 |
32 other studies available for hydroxychloroquine and Hypermelanosis
| Article | Year |
|---|---|
Hydroxychloroquine-Induced Oral Mucosal Hyperpigmentation.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Hyperpigmentation | 2023 |
Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Hyperpigmen | 2020 |
The First Case of Skin Hyperpigmentation and Melanonychia Due to Hydroxychloroquine in Chile.
Topics: Chile; Humans; Hydroxychloroquine; Hyperpigmentation; Nail Diseases; Nails, Malformed | 2020 |
Hydroxychloroquine-induced Hyperpigmentation.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Hyperpigmentation | 2020 |
Addisonian-like acrofacial hyperpigmentation following long-term hydroxychloroquine therapy in oral lichen planus.
Topics: Humans; Hydroxychloroquine; Hyperpigmentation; Lichen Planus; Lichen Planus, Oral | 2021 |
Lichen planopilaris with significant post-inflammatory pigmentary alteration.
Topics: Adult; Dermatologic Agents; Diagnosis, Differential; Humans; Hydroxychloroquine; Hyperpigmentation; | 2021 |
Hydroxychloroquine-related hyperpigmentation.
Topics: Adult; Antirheumatic Agents; Cheek; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Leg; Lupu | 2022 |
Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases.
Topics: Adult; Anticoagulants; Antimalarials; Antirheumatic Agents; Cross-Sectional Studies; Female; Humans; | 2017 |
Hydroxychloroquine sulphate therapy of erosive oral lichen planus.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Exanthema; Female; Humans; Hydroxychloroquine; Hyperpigm | 2019 |
Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine.
Topics: Color; Female; Hemorrhage; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematosus, Syste | 2019 |
Woman in grey: hydroxychloroquine-induced hyperpigmentation.
Topics: Aged, 80 and over; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Lupu | 2018 |
Hydroxychloroquine-Associated Hyperpigmentation in Chilblain Lupus Erythematosus.
Topics: Chilblains; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematosus, Cutaneous; Lupus Ery | 2020 |
Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Topics: Adult; Antirheumatic Agents; Case-Control Studies; Contusions; Ecchymosis; Female; Humans; Hydroxych | 2013 |
Hydroxychloroquine-induced hyperpigmentation.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematosus, Sy | 2013 |
[Sclerodermatous changes in porphyria cutanea tarda: six cases].
Topics: Adrenal Cortex Hormones; Aged; Alcoholism; Alopecia; Diagnosis, Differential; Female; Humans; Hydrox | 2013 |
Hydroxycholoroquine-induced hyperpigmentation.
Topics: Antirheumatic Agents; Female; Foot; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematos | 2013 |
Hydroxychloroquine-induced hyperpigmentation.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Eruptions; Female; Humans; Hydroxychloroquine; Hyp | 2014 |
Hydroxychloroquine-induced hyperpigmentation of the skin.
Topics: Adult; Antirheumatic Agents; Arthritis; Female; Humans; Hydroxychloroquine; Hyperpigmentation | 2015 |
Serpentine supravenous hyperpigmentation due to hydroxychloroquine.
Topics: Antimalarials; Humans; Hydroxychloroquine; Hyperpigmentation; Male; Middle Aged | 2016 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2008 |
Hydroxychloroquine-induced hyperpigmentation: a case report.
Topics: Antimalarials; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Middle Aged; Sjogren's Syndrom | 2008 |
Persistent cutaneous hyperpigmentation due to hydroxychloroquinone one year after therapy discontinuation.
Topics: Aged; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Time Factors | 2009 |
A progressive scalp lesion.
Topics: Alopecia; Antimalarials; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Hypopigmentation; Lu | 2010 |
[Skin pigmentation in a patient with systemic lupus erythematosus].
Topics: Female; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematosus, Systemic | 2010 |
Hyperpigmented forearms and nail: a quiz.
Topics: Aged; Biopsy; Female; Forearm; Hemosiderin; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Ery | 2010 |
Graham-Little-Piccardi-Lassueur syndrome.
Topics: Adult; Alopecia; Axilla; Doxycycline; Female; Groin; Humans; Hydroxychloroquine; Hyperpigmentation; | 2011 |
Hydroxychloroquine-induced hyperpigmentation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans | 2012 |
Isolated hyperpigmentation of the oral mucosa due to hydroxychloroquine.
Topics: Antimalarials; Diagnosis, Differential; Drug Eruptions; Female; Humans; Hydroxychloroquine; Hyperpig | 2012 |
Clinical images: Hydroxychloroquine-associated mucocutaneous hyperpigmentation.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Hyperpigmentation | 2002 |
Cutaneous hyperpigmentation during therapy with hydroxychloroquine.
Topics: Dermatologic Agents; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Middle Aged; Mixed Conne | 2004 |
Cutaneous hyperpigmentation during therapy with hydroxychloroquine.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Hyperpigment | 2007 |
[Hirsutism treated by estrogens and anti-estrogens: disclosure of porphyria cutanea tarda. Association with chronic hepatitis C].
Topics: Adult; Estrogen Antagonists; Female; Hepatitis C; Hepatitis, Chronic; Hirsutism; Humans; Hydroxychlo | 1994 |